This study evaluated the clinical effectiveness of continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in managing type 1 diabetes mellitus (T1DM) among Libyan patients. Conducted in June 2022, the comparative cross-sectional study compared 32 CSII users (≥6 months of therapy) with 30 MDI controls through structured questionnaires. The CSII group demonstrated significantly better outcomes, including superior glycemic control (mean HbA1c 6.97±0.61 vs 9.8±1.99), reduced acute complications (hypoglycemia: 31.3% vs 50%; DKA: 3.1% vs 20%), and higher treatment adherence (81.3% vs 43.3%). Glycemic improvement correlated strongly with pump duration, showing progressive HbA1c reduction from 7.2±0.2 at 6-12 months to 6.89±0.16 after >2 years of use. The CSII cohort also exhibited more favorable BMI distributions (78.1% healthy weight vs 33.3%) and reported enhanced quality of life. Despite these benefits, challenges in maintenance supply availability were reported. These findings provide compelling evidence for CSII's clinical superiority in Libya's context and support its wider implementation through national programs that address current supply chain limitations while ensuring proper patient training and follow-up support. The results highlight CSII as a valuable therapeutic advancement for T1DM management in resource-constrained settings
Read full abstract- All Solutions
Editage
One platform for all researcher needs
Paperpal
AI-powered academic writing assistant
R Discovery
Your #1 AI companion for literature search
Mind the Graph
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus - Support
Overview
1360 Articles
Published in last 50 years
Articles published on Wider Implementation
Authors
Select Authors
Journals
Select Journals
Duration
Select Duration
1254 Search results
Sort by Recency